All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2017-08-18T07:48:37.000Z

Lenalidomide monotherapy for R/R MCL demonstrates efficacy and predictable safety profile in long-term analysis of three phase II trials

Aug 18, 2017
Share:

Bookmark this article

In the American Journal of Hematology, last month Thomas E. Witzig, MD, from the Mayo Clinic, Rochester, MN, US, and colleagues published a report consolidating data from three phase II trials (NHL-002, NHL-003, and MCL-001) to ultimately provide long-term efficacy and safety data for the immunomodulatory agent lenalidomide in the treatment of Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL).

  • NHL-002 (NCT00179660) was conducted between August 2005 and September 2006 at 8 centers in the US and Canada, and included 15/49 patients (31%) with R/R MCL
  • NHL-003 (NCT00413036) occurred between November 2006 and March 2008 at 48 centers based in Western Europe (n=28), the US (n=17), and Canada (n=3), and included 57/217 patients (26%) with R/R MCL
  • MCL-001 (EMERGE; NCT00737529) was a global, multicenter, open-label trial of lenalidomide monotherapy in 134 patients with R/R MCL. This trial took place between January 2009 and March 2013 at 45 centers based in the US (n=18), Europe (n=18), Asia (n=8), and Colombia (n=1)

In all three studies, oral lenalidomide monotherapy was given at a dose of 25mg/day on days 1–21 of each 28-day cycle as tolerated for up to 52 weeks in NHL-002 or until disease progression in NHL-003 and MCL-001. Lenalidomide was administered at a 10mg dose for patients with moderate renal insufficiency characterized by creatinine clearance ≥30 to <60mL/min (MCL-001 only). The primary outcome measure for all three studies was best Overall Response Rate (ORR), in addition to Duration of Response (DoR) in the MCL-001 trial.

Key Highlights:

Patient disposition and baseline characteristics:

  • In total, 206 patients (pts) with R/R MCL included in the current analysis
  • Median age = 67 years (33–84); 63% of pts (n=130) were ≥65 years
  • MCL stage III/IV disease = 91% of pts (n=187)
  • Eastern Cooperative Oncology Group performance status 0–1 = 88% of pts (n=181)
  • High (≥6.2) MIPI = 34% of pts (n=71)
  • Elevated lactate dehydrogenase = 42% of pts (n=87)
  • High tumor burden = 52% of pts (n=108); bulky disease = 30% of pts (n=62)
  • Median number of prior therapies = 4 (range, 1–13); 75% had received ≥3 prior therapies
  • Prior therapies included regimens containing anthracyclines (96%; n=198), bortezomib (76%; n=157), and rituximab (98%; n=201)
  • Median time from last prior therapy = 3.3 months (range, 1–58.5)

Efficacy:

  • ORR = 33%; CR/CRu = 11% (n=11); PR = 22% (n=46); SD = 32% (n=65); PD = 24% (n=50)
  • Median Time To Response (TTR): in all responders = 2.2 months (range, 1.6–24.2); in CR/CRu pts = 2.0 months (range, 1.6–20.9)
  • Median DoR: in all responders = 16.6 months (95% CI, 11.1–29.8); in CR/CRu pts = 28.1 months (95% CI, 11.0–NR); in PR pts = 11.1 months (range, 6.5–26.7)
  • Median PFS = 5.5 months (95% CI, 3.7–7.4)
  • Median OS = 24.4 months (95% CI, 19.0–30.0)
  • In post-bortezomib pts (n=157):
    • ORR = 31% (n=48); CR/CRu = 9% (n=14); PR = 22% (n=34); SD = 31% (n=48); PD = 25% (n=39)
    • Median TTR = 2.3 months (range, 1.6–15.9)
    • Median DoR = 16.6 months (95% CI, 8.9–28.1)
    • Median PFS = 4.5 months (95% CI, 3.7–7.2)
    • Median OS = 21.5 months (95% CI, 13.7–28.4)
  • ORR with lenalidomide monotherapy in the combined cohort was consistent across patient subgroups according to baseline demographics, clinical characteristics, or type of prior therapy

Safety:

  • Average daily dose of lenalidomide: all MCL pts = 21mg; post-bortezomib pts = 20mg
  • Median duration of treatment: all MCL pts = 106 days; post-bortezomib pts = 101 days
  • Proportion of pts who received ≥12 cycles of lenalidomide = 26%
  • Proportion of pts who experienced dose interruption/reduction due to AEs: in all MCL pts = 59%; in post-bortezomib pts = 58%
  • Proportion of pts who discontinued lenalidomide due to AEs = 13%
  • Myelosuppression was the most common grade 3–4 toxicity
  • Incidence of grade 3–4: neutropenia = 42%; thrombocytopenia = 28%; anemia = 11%; febrile neutropenia = 6%
  • Most common non-hematologic toxicities: fatigues (7%), diarrhea (6%), dyspnea (5%), and pneumonia (4%)
  • Other AEs of interest: deep vein thrombosis (grade ≥3, 3%; 1 dose interruption), pulmonary embolism (2%, resolved without interruption), tumor flare reaction (14 pts in total; grade I–II, 7%)
  • In total, 113 pts died during, or within 30 days of last dose, of treatment with lenalidomide
  • Most common causes of death: MCL (n=78), other known causes (n=22), unknown causes (n=11), and toxicity (n=2)
  • Invasive Secondary Primary Malignancies (SPM) reported in 13 pts (6%) and included hematologic malignancies in 3 pts (1 AML; 1 MDS; 1 MDS to AML) and solid tumors in 10 pts
  • Median time to onset of invasive SPM = 15.4 months (range, 1.2–52.1)

The authors concluded that this long-term data indicates that lenalidomide monotherapy achieved a “noteworthy” ORR of 33% and has a “consistent, predictable, and manageable” toxicity profile demonstrated across numerous phase II trials in heavily pre-treated, advanced-stage patients with R/R MCL. The authors emphasized the importance of understanding the long-term outcomes and toxicities of novel agents, which are becoming more frequently used as first-line therapy for the treatment of MCL.

Abstract:

Mantle cell lymphoma (MCL) is a type of non-Hodgkin lymphoma (NHL) with aggressive disease characteristics resulting in multiple relapses after initial treatment. Lenalidomide is an immunomodulatory agent approved in the US for patients with relapsed/refractory MCL following bortezomib based on results from 3 multicenter phase II studies (2 including relapsed/refractory aggressive NHL and 1 focusing on MCL post-bortezomib). The purpose of this report is to provide longer follow-up on the MCL-001 study (follow-ups were 6.8 [NHL-002], 7.6 [NHL-003], and 52.2 [MCL-001] months). The 206 relapsed MCL patients treated with single-agent lenalidomide (25 mg/day PO, days 1-21 every 28 days) had a median age of 67 years (63% ≥65 years), 91% with stage III/IV disease, and 50% with ≥4 previous treatment regimens. With a median follow-up of X, the combined best overall response rate was 33% (including 11% with complete remission [CR]/unconfirmed CR). Lenalidomide produced rapid and durable responses with a median time to response of 2.2 months and median duration of response of 16.6 months (95% CI: 11.1%-29.8%). The safety profile was consistent and manageable; myelosuppression was the most common adverse event. Overall, single-agent lenalidomide showed consistent efficacy and safety in multiple phase II studies of heavily pretreated patients with relapsed/refractory MCL, including those previously treated with bortezomib.

  1. Witzig T.E. et al. Long-Term Analysis of Phase II Studies of Single-Agent Lenalidomide in Relapsed/Refractory Mantle Cell Lymphoma. American Journal of Hematology. 2017 Jul 11. DOI: 10.1002/ajh.24854. [Epub ahead of print].

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox